Last reviewed · How we verify
TL-925
At a glance
| Generic name | TL-925 |
|---|---|
| Sponsor | Telios Pharma, Inc. |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Evaluation of TL-925 for the Treatment of Seasonal Allergic Conjunctivitis (PHASE2)
- Evaluation of TL-925 for the Treatment of Allergic Conjunctivitis (PHASE2)
- A Study of TL-925 Ophthalmic Emulsion as a Treatment for Dry Eye Disease (PHASE2)
- A Study Of TL-925 For The Treatment of AC (PHASE2)
- A Study of TL-925 for the Treatment of Allergic Conjunctivitis (PHASE2)
- A Study of TL-925 as a Treatment for Dry Eye Disease (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- TL-925 CI brief — competitive landscape report
- TL-925 updates RSS · CI watch RSS
- Telios Pharma, Inc. portfolio CI